A phase III trial of PPP001 (smokeable marijuana) in terminal cancer patients

Trial Profile

A phase III trial of PPP001 (smokeable marijuana) in terminal cancer patients

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Marijuana (Primary)
  • Indications Cancer pain; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Tetra Bio Pharma
  • Most Recent Events

    • 18 Sep 2017 According to a Tetra Bio Pharma media release, the company will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate this phase III clinical trial of PPP001 in terminal cancer patients.
    • 15 Jun 2017 New trial record
    • 07 Jun 2017 According to a Tetra Bio-Pharma media release, the company expects to launch this trial in collaboration with Quebec's leading medical cannabis clinic, Sante Cannabis by the fourth quarter of 2017 or first quarter of 2018. Dr. Antonio Vigano, will be the lead trial physician.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top